Literature DB >> 16537444

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Weiru Wang1, Adhirai Marimuthu, James Tsai, Abhinav Kumar, Heike I Krupka, Chao Zhang, Ben Powell, Yoshihisa Suzuki, Hoa Nguyen, Maryam Tabrizizad, Catherine Luu, Brian L West.   

Abstract

Protein kinases are a large family of cell signaling mediators undergoing intensive research to identify inhibitors or modulators useful for medicine. As one strategy, small-molecule compounds that bind the active site with high affinity can be used to inhibit the enzyme activity. X-ray crystallography is a powerful method to reveal the structures of the kinase active sites, and thus aid in the design of high-affinity, selective inhibitors. However, a limitation still exists in the ability to produce purified kinases in amounts sufficient for crystallography. Furthermore, kinases exist in different conformation states as part of their normal regulation, and the ability to prepare crystals of kinases in these various states also remains a limitation. In this study, the c-Abl, c-Src, and c-Met kinases are produced in high yields in Escherichia coli by using a bicistronic vector encoding the PTP1B tyrosine phosphatase. A 100-fold lower dose of the inhibitor, Imatinib, was observed to inhibit the unphosphorylated form of c-Abl kinase prepared by using this vector, compared to the phosphorylated form produced without PTP1B, consistent with the known selectivity of this inhibitor for the unactivated conformation of the enzyme. Unphosphorylated c-Met kinase produced with this vector was used to obtain the crystal structure, at 2.15-A resolution, of the autoinhibited form of the kinase domain, revealing an intricate network of interactions involving c-Met residues documented previously to cause dysregulation when mutated in several cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537444      PMCID: PMC1450123          DOI: 10.1073/pnas.0600048103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Two mutations affecting conserved residues in the Met receptor operate via different mechanisms.

Authors:  D Maritano; P Accornero; N Bonifaci; C Ponzetto
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

Authors:  L Schmidt; K Junker; G Weirich; G Glenn; P Choyke; I Lubensky; Z Zhuang; M Jeffers; G Vande Woude; H Neumann; M Walther; W M Linehan; B Zbar
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

4.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.

Authors:  M F Di Renzo; M Olivero; T Martone; A Maffe; P Maggiora; A D Stefani; G Valente; S Giordano; G Cortesina; P M Comoglio
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

5.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

6.  Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.

Authors:  M Olivero; G Valente; A Bardelli; P Longati; N Ferrero; C Cracco; C Terrone; S Rocca-Rossetti; P M Comoglio; M F Di Renzo
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

7.  Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met.

Authors:  E Villa-Moruzzi; F Puntoni; A Bardelli; E Vigna; S De Rosa; P M Comoglio
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

8.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

Authors:  W S Park; S M Dong; S Y Kim; E Y Na; M S Shin; J H Pi; B J Kim; J H Bae; Y K Hong; K S Lee; S H Lee; N J Yoo; J J Jang; S Pack; Z Zhuang; L Schmidt; B Zbar; J Y Lee
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

9.  Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx.

Authors:  Daniel M Aebersold; Olfert Landt; Sylvie Berthou; Günther Gruber; Karl T Beer; Richard H Greiner; Yitzhak Zimmer
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

10.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Authors:  Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-26       Impact factor: 11.205

View more
  26 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Abl kinase constructs expressed in bacteria: facilitation of structural and functional studies including segmental labeling by expressed protein ligation.

Authors:  Rong Xu; Dongsheng Liu; David Cowburn
Journal:  Mol Biosyst       Date:  2012-05-16

Review 3.  Receptor tyrosine kinases: mechanisms of activation and signaling.

Authors:  Stevan R Hubbard; W Todd Miller
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

4.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.

Authors:  Anshuman Dixit; Ali Torkamani; Nicholas J Schork; Gennady Verkhivker
Journal:  Biophys J       Date:  2009-02       Impact factor: 4.033

5.  Structural basis for selective small molecule kinase inhibition of activated c-Met.

Authors:  Keith W Rickert; Sangita B Patel; Timothy J Allison; Noel J Byrne; Paul L Darke; Rachael E Ford; David J Guerin; Dawn L Hall; Maria Kornienko; Jun Lu; Sanjeev K Munshi; John C Reid; Jennifer M Shipman; Elizabeth F Stanton; Kevin J Wilson; Jonathon R Young; Stephen M Soisson; Kevin J Lumb
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

6.  Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.

Authors:  Kuntal Pal; Abhishek Bandyopadhyay; X Edward Zhou; Qingping Xu; David P Marciano; Joseph S Brunzelle; Smitha Yerrum; Patrick R Griffin; George Vande Woude; Karsten Melcher; H Eric Xu
Journal:  Structure       Date:  2017-05-18       Impact factor: 5.006

7.  Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Authors:  Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

Review 8.  The insulin receptor: both a prototypical and atypical receptor tyrosine kinase.

Authors:  Stevan R Hubbard
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

9.  Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase.

Authors:  Elham Behshad; Ronald M Klabe; Alexander Margulis; Mary Becker-Pasha; Mark J Rupar; Paul Collier; Phillip C Liu; Gregory F Hollis; Timothy C Burn; Richard Wynn
Journal:  Curr Chem Genomics       Date:  2010-04-23

10.  Sequence and structure signatures of cancer mutation hotspots in protein kinases.

Authors:  Anshuman Dixit; Lin Yi; Ragul Gowthaman; Ali Torkamani; Nicholas J Schork; Gennady M Verkhivker
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.